Dongsung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dongsung Kim has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Cuevas-Navarro
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications - Piro Lito
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY
2 shared publications Yasin Pourfarjam
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY 10065, USA
2 shared publications- Yulei Zhao
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY 10065, USA
2 shared publications - Abby Marquez
Revolution Medicines, Inc., Redwood City, California
1 shared publication Adrian L. Gill
Department of Discovery Chemistry, Revolution Medicines, Inc., Redwood City, CA 94063, USA
1 shared publication
Latest Publications
- 12 August 2026
- Published by Springer Nature in Nature Chemical Biology
- p. 1-2
A dual assault on KRAS
- Open Access
- 12 November 2025
- Published by Elsevier in Poultry Science
- Vol. 105 (1) , 106096
CRISPR/Cas9 Gene Editing of Turkey Cells Using Adenoviral Delivery Running Head: RESEARCH NOTE
- 12 November 2025
- Published by Elsevier in Poultry Science
- Vol. 105 (1) , 106096
Open AccessCRISPR/Cas9 Gene Editing of Turkey Cells Using Adenoviral Delivery Running Head: RESEARCH NOTE
- Top Cited Papers
- 18 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6659) , 794-799
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product–inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRAS G12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRAS G12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRAS G12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).
- 18 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6659) , 794-799
Top Cited PapersChemical remodeling of a cellular chaperone to target the active state of mutant KRAS
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product–inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRAS G12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRAS G12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRAS G12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).
- Top Cited PapersOpen Access
- 31 May 2023
- Published by Springer Nature in Nature
- Vol. 619 (7968) , 160-166
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients1–7. Whether inactive-state selective inhibition can be used to therapeutically target non-G12C KRAS mutants remains under investigation. Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially and with high affinity to the inactive state of KRAS while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active state and an inactive state in cancer cells and are dependent on nucleotide exchange for activation. Pan-KRAS inhibitors, such as the one described here, have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.
- 31 May 2023
- Published by Springer Nature in Nature
- Vol. 619 (7968) , 160-166
Top Cited PapersOpen AccessPan-KRAS inhibitor disables oncogenic signalling and tumour growth
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients1–7. Whether inactive-state selective inhibition can be used to therapeutically target non-G12C KRAS mutants remains under investigation. Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially and with high affinity to the inactive state of KRAS while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active state and an inactive state in cancer cells and are dependent on nucleotide exchange for activation. Pan-KRAS inhibitors, such as the one described here, have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.
- Open Access
- 31 December 2006
- Published by Korea Ocean Research and Development Institute in Ocean and Polar Research
- Vol. 28 (4) , 385-393
Performance Analysis of Intake Screens in Power Plants on Mass Impingement of Marine Organisms
- 31 December 2006
- Published by Korea Ocean Research and Development Institute in Ocean and Polar Research
- Vol. 28 (4) , 385-393
Open AccessPerformance Analysis of Intake Screens in Power Plants on Mass Impingement of Marine Organisms